About this trial
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Eligibility criteria
Qualifiers
Age ≥18
Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology
ECOG:0-2
Life expectancy ≥ 3 months
Disqualifiers
Diagnosis of acute promyelocytic leukemia (APL)
Central nervous system leukemia
Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker; Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);
Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg; History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);
Trial design
Treatments tested in this trial
- venetoclax combining chidamide and azacitidine (VCA)
Treatment groups
Sponsors and collaborators
The First Affiliated Hospital of Xiamen University
Lead sponsor
Fujian Provincial Hospital
Collaborator
Fujian Cancer Hospital
Collaborator
Zhangzhou manicipal hospital of Fujian Province
Collaborator
Jieyang People's Hospital
Collaborator
Dongguan People's Hospital
Collaborator
Huizhou Municipal Central Hospital
Collaborator